Providence Multiple Sclerosis Center Takes Part in New Medication Trials

Mar. 17, 2008

PORTLAND, Ore. – Providence Multiple Sclerosis Center is taking part in the clinical trial of a new investigative, oral medication for treating the relapsing form of multiple sclerosis (MS). Dr. Stanley Cohan, medical director of Providence Multiple Sclerosis Center, is currently enrolling patients for this phase three study of the drug, which is called BG00012.

If this drug reduces immune system attacks of the brain, it could be an important new treatment option. “A pill would eliminate the necessity for injections, reducing discomfort and inconvenience for MS patients,” says Dr. Cohan.

In earlier clinical trials, BG00012 resulted in a reduction in relapses. To qualify for the current trial, patients must have the relapsing form of MS, and must have had at least one relapse in the past 12 months.

Multiple sclerosis is a chronic, inflammatory disease that affects the central nervous system. It can cause a variety of symptoms including muscle weakness, visual problems, difficulties with coordination and speech, severe fatigue, and cognitive impairment.

An estimated 400,000 people in the United States have MS. Every week in the U.S., doctors diagnose 200 new cases. Women are two to three times more likely than men to develop the disease.

Patients wishing to learn more about this new MS trial should contact Providence Multiple Sclerosis Center at 503-216-1017.